BLNK and cancer: FAM83H-Nu-positive BCA patients had an 8.098-fold greater risk of death (95% CI, 3.409–19.237) and a 5.268-fold higher risk of death or cancer relapse (95% CI, 2.939–9.441) than patients who were negative for FAM83H-Nu (Table 2).